Physician profile
Joseph E Khabbaza
NPI 1760645428
$655,372.25
in general payments reported to CMS, 2019-2025
31 companies · $210K in 2025
The $210K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $27K · 2021: $70K · 2022: $75K · 2023: $133K · 2024: $87K · 2025: $210K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $251K · Consulting Fee: $104K · Travel and Lodging: $59K · Food and Beverage: $16K · Education: $21.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $251,179.60 |
| Consulting Fee | $103,720.00 |
| Travel and Lodging | $58,708.98 |
| Food and Beverage | $15,910.29 |
| Education | $21.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $340,850.33 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $150,980.48 | 2019-2025 | Dupixent |
| Genzyme Corporation | $126,439.27 | 2021-2025 | |
| Baxter Healthcare | $15,231.43 | 2022-2025 | Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care, Hillrom - Vest System Model 205 Acute Care |
| Tactile Systems Technology INC | $13,272.38 | 2024-2025 | Flexitouch Plus, Entre Plus |
| Astrazeneca Pharmaceuticals Lp | $5,290.22 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Hill-Rom Company, INC | $875.00 | 2021 | |
| Glaxosmithkline, LLC. | $616.21 | 2020-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $342.71 | 2021-2025 | Tyvaso, Orenitram, Tyvaso |
| Teva Pharmaceuticals USA, INC. | $245.96 | 2021-2023 | Airduo Digihaler |
| Verona Pharma, INC. | $201.97 | 2025 | Ohtuvayre |
| Electromed, INC. | $185.38 | 2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $172.34 | 2020-2024 | |
| Mylan Specialty L.P. | $138.61 | 2021-2024 | Yupelri |
| Amgen INC. | $59.81 | 2023-2025 | Tezspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.48 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $51.88 | 2023 | Opsumit |
| Advanced Respiratory, INC | $51.14 | 2019-2021 | |
| Lilly USA, LLC | $47.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $40.12 | 2024 | Zerbaxa, Recarbrio, Dificid |
| Averitas Pharma INC. | $39.01 | 2023-2024 | Qutenza |
| Relievant Medsystems, INC. | $23.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.80 | 2020 | |
| Emd Serono, INC. | $21.45 | 2021 | |
| Mallinckrodt Hospital Products INC. | $21.04 | 2020 | |
| Grt US Holding, INC. | $20.38 | 2022 | |
| Viatris Specialty LLC | $17.35 | 2025 | Yupelri |
| Genentech USA, INC. | $16.39 | 2021 | |
| Z-Medica, LLC | $14.54 | 2019 | |
| Pfizer INC. | $13.34 | 2019 | |
| Hikma Pharmaceuticals USA | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Khabbaza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.